Leukogene Therapeutics Announces Two Presentations at the AACR Annual Meeting 2026 Highlighting MHC Class II-Engager Immunotherapies

Leukogene Therapeutics, Inc., an early‑stage oncology company developing MHC class II-engager immunotherapies for immunologically cold cancers, today announced two poster presentations at the American ...
Nature

MHC Class II Molecules and Antigen Presentation

MHC Class II molecules are integral to the adaptive immune response, serving as specialised antigen-presenting proteins on the surface of professional antigen-presenting cells. They bind peptide ...
ascopubs.org

First-line chemoimmunotherapy in metastatic breast carcinoma: Effect of a combination of paclitaxel and LAG-3-ig (IMP321), a novel MHC class II agonist, on T-cell responses and ...

A phase I study of bevacizumab in combination with sunitinib, sorafenib, and erlotinib plus cetuximab, and trastuzumab plus lapatinib. Background: IMP321 is a recombinant soluble LAG-3Ig fusion ...
EurekAlert!

A missing link in the MHC class divergence puzzle: Class II came first

Which came first, MHC class I or MHC class II? For decades, it has been debated which of these two similar classes came first in evolution. Now, Keiichiro Hashimoto and his group at Fujita Health ...